A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

Marc S. Ernstoff,Wen Wee Ma,Frank Yung-Chin Tsai,Pamela N. Munster,Tian Zhang,Walid S. Kamoun,J. Marc Pipas,Sharon Chen,Sergio Santillana,Vasileios Askoxylakis

A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors.

2018

Marc S. Ernstoff
Wen Wee Ma
Frank Yung-Chin Tsai
Pamela N. Munster
Tian Zhang
Walid S. Kamoun
J. Marc Pipas
Sharon Chen
Sergio Santillana
Vasileios Askoxylakis

TPS2604Background: Ephrin receptor A2 (EphA2) is expressed in cancer and stroma cells in a wide range of solid tumors. MM-310 is an EphA2-targeting liposomal form of a docetaxel prodrug. Preclinica...

Keywords:

Safety pharmacology
Pathology
Medicine
Erythropoietin-producing hepatocellular (Eph) receptor
Prodrug
in patient
Docetaxel
EPH receptor A2
Stromal cell
Cancer
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations